NCT04177082View on ClinicalTrials.gov

Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

PHASE1CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

May 5, 2022

Study Completion Date

May 5, 2022

Conditions
KeratoconusPellucid Marginal Corneal DegenerationCorneal DegenerationCorneal Ectasia
Interventions
COMBINATION_PRODUCT

PXL-330 Platinum device for crosslinking with Peschke riboflavin solution

Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea

Trial Locations (1)

75231

Cornea Associates of Texas, Dallas

Sponsors
All Listed Sponsors
lead

Cornea Associates of Texas

OTHER

NCT04177082 - Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution | Biotech Hunter | Biotech Hunter